Pharma BD Deal Intelligence
Novartis's $3.1B reacquisition of Anthos Therapeutics looks like a mixed bet: the once-monthly Factor XI/XIa inhibitor abelacimab retains its atrial-fibrillation stroke-prevention opportunity, with Phase 3 LILAC-TIMI 76 still enrolling toward a 2028 filing, but Novartis killed both cancer-associated thrombosis Phase 3 trials in early 2026 after data showed it wouldn't beat Eliquis, narrowing the asset to a single indication.
Novartis bets up to $3.1 billion to buy back its own blood thinner abelacimab through the Anthos acquisition, essentially repurchasing a drug it had originally…
Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial. Novartis has terminated two phase 3 trials for the abelacimab antibody…
MAGNOLIA (abelacimab vs dalteparin, GI/GU cancer VTE): OverallStatus TERMINATED, WhyStopped 'Sponsor Decision', status verified 2026-04.
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Novartis acquired Anthos Therapeutics (a 2019 Blackstone Life Sciences / Novartis spinout) for up to $3.1B — $925M upfront plus regulatory and sales milestones — announced Feb 11, 2025 and closed Apr 3, 2025, reacquiring the Factor XI/XIa inhibitor abelacimab. Abelacimab is a once-monthly subcutaneous fully human monoclonal antibody positioned as a hemostasis-sparing anticoagulant. The lead opportunity is stroke prevention in atrial fibrillation: the Phase 3 LILAC-TIMI 76 trial (NCT05712200) remains in recruitment with completion expected Oct 2026 and a Novartis-targeted 2028 regulatory filing. The secondary cancer-associated thrombosis (CAT) program has since failed: in early 2026 Novartis terminated both Phase 3 CAT studies — ASTER (NCT05171049, vs apixaban) after a data review indicated abelacimab would not beat Eliquis, and MAGNOLIA (NCT05171075, vs dalteparin in GI/GU cancer VTE) — ending abelacimab development in CAT and narrowing the asset's value to the AF indication.
Abelacimab enters the approximately $20B+ oral anticoagulant category where Factor XI inhibition is the next-generation bleeding-reduction thesis. Factor XI/XIa inhibitors (direct MOA): BMS/Janssen's milvexian (oral small molecule, Phase 3 LIBREXIA-AF, -ACS, -SYNERGY program) and Bayer's asundexian (oral small molecule, Phase 3 OCEANIC-AF halted August 2023 for inferior efficacy vs. apixaban, continuing OCEANIC-STROKE) are the key competitors; Abelacimab is the only monoclonal antibody in the class and the only one with AZALEA-TIMI 71 data showing 67% major/CRNM bleeding reduction vs. rivaroxaban (halted early for efficacy). Factor Xa inhibitors (incumbent standard): BMS/Pfizer's Eliquis (apixaban, $18.4B combined 2024 sales), Bayer/J&J's Xarelto (rivaroxaban, approximately $7B 2024), and Daiichi Sankyo's Savaysa/Lixiana (edoxaban) define the DOAC franchise. Direct thrombin inhibitors: Boehringer's Pradaxa (dabigatran) remains in late lifecycle. Vitamin K antagonists: generic warfarin persists in cost-sensitive segments. For a commercial lead, abelacimab's once-monthly SC dosing and bleeding profile are differentiators, but milvexian's oral formulation is the true franchise threat if Phase 3 wins — Novartis must target high-bleeding-risk AF subpopulations where Eliquis discontinuation is common to carve defensible share.
Cancer-associated thrombosis (CAT) is a differentiated AF subsegment where bleeding risk-benefit is particularly challenging for DOACs. Factor XI/XIa inhibitors (abelacimab's class): Abelacimab's ASTER and MAGNOLIA Phase 3 CAT trials reported a ~60% reduction in VTE recurrence vs. apixaban with a favorable bleeding profile; no other FXI asset has CAT-specific Phase 3 data — BMS/J&J's milvexian and Bayer's asundexian remain AF/ACS-focused. Factor Xa inhibitors (incumbent standard): BMS/Pfizer's Eliquis (apixaban) holds the CARAVAGGIO-based ASCO/ISTH preferred-agent position; Bayer's Xarelto (rivaroxaban, SELECT-D, CASSINI) retains GI-cancer caution due to bleeding signal; Daiichi's Lixiana/Savaysa (edoxaban, Hokusai-VTE Cancer) is the original approved DOAC in CAT. Low-molecular-weight heparins (prior standard): Sanofi's Lovenox (enoxaparin) and Pfizer's Fragmin (dalteparin, CLOT-approved) retained share in GI/GU malignancies pre-DOAC shift. Vitamin K antagonists: warfarin has been largely displaced. For a commercial lead, CAT is an underserved subpopulation (~900K US CAT patients, high recurrence on DOACs); abelacimab's selective FXI blockade could position as the preferred agent in GI/GU cancers where Eliquis bleeding risk limits uptake, and ASTER/MAGNOLIA data gives Novartis label-differentiation optionality.
Novartis completed $3.1B acquisition of Anthos Therapeutics, gaining abelacimab, a Factor XI inhibitor for stroke prevention and thrombosis.
Novartis terminated abelacimab's two Phase 3 cancer-associated-thrombosis trials — ASTER (vs apixaban; halted after a data review indicated it would not beat Eliquis) and MAGNOLIA (vs dalteparin in GI/GU cancer VTE) — ending CAT development. The Phase 3 atrial-fibrillation program (LILAC-TIMI 76) continues toward a targeted 2028 filing.
Mixed. The closed $3.1B M&A's value now rests entirely on the AF indication: the secondary cancer-associated-thrombosis program (ASTER, MAGNOLIA) was terminated in early 2026 after ASTER would not beat Eliquis. Abelacimab's pivotal AF trial (LILAC-TIMI 76) remains ongoing, completion Oct 2026, with a Novartis-targeted 2028 filing — outcome still pending.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Anthos Therapeutics (this deal) | 2025 | $3.1B | 74 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2025 deals · Novartis AG deals · Cardiovascular deals